Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
befotertinib + rifampicin
- Development stage
- Phase 1
- Lead developer
- Betta Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Befotertinib + rifampicin is a drug-drug interaction study regimen evaluated in a Phase 1 clinical trial. Befotertinib (brand name: Surmana) is an orally administered, highly selective, irreversible, third-generation small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) developed by Betta Pharmaceuticals and InventisBio. It is approved in China for the treatment of EGFR T790M mutation-positive non-small cell lung cancer (NSCLC). Rifampicin is a potent inducer of cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) via activation of the pregnane X receptor (PXR). In this clinical trial, rifampicin is not used as a therapeutic co-drug but rather as a probe agent to evaluate the impact of strong CYP3A4 induction on the pharmacokinetics, safety, and tolerability of befotertinib in healthy participants.
- Other names
- D-0316 + rifampicinD-0316 + rifampinSurmana + Rifadinbefotertinib + rifampinbefotertinib and rifampicinbefotertinib and rifampin
02
Targets
ABCG2 (Breast cancer resistance protein)EGFR (Epidermal growth factor receptor)
Beyond the preview
Go deeper on befotertinib + rifampicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on befotertinib + rifampicin.